Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Trial achieved primary reversal endpoint in older volunteers
Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported
https://finance.yahoo.com/news/phasebio-announces-positive-results-phase-120000222.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.